GeneDx (WGS) Stock Price, News & Analysis

Company Overview

GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results.

The company’s testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk.

Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care. The company is based in the United States and serves healthcare providers and patients through its diagnostic services.

Key Stats

• Today's Range: $52.89 to $58.07
• 50-Day Range: $56.15 to $104.95
• 52-Week Range: $32.21 to $170.87
• Volume: 438,642 shs
• Average Volume: 923,591 shs
• Market Capitalization: $1.65 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $90.14
• Consensus Rating: Moderate Buy

GeneDx Stock Analysis - MarketRank™

GeneDx scored higher than 64% of companies evaluated by MarketBeat, and ranked 370th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

GeneDx has a consensus price target of $90.86, representing about 38.2% upside from its current price of $65.72.

Amount of Analyst Coverage

GeneDx has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GeneDx are expected to grow in the coming year, from ($0.41) to $1.15 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeneDx is -18.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeneDx is -18.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeneDx has a P/B Ratio of 6.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.98% of the float of GeneDx has been sold short.

Short Interest Ratio / Days to Cover

GeneDx has a short interest ratio ("days to cover") of 8.73.

Change versus previous month

Short interest in GeneDx has recently increased by 7.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeneDx does not currently pay a dividend.

Dividend Growth

GeneDx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.72

News Sentiment

GeneDx has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for GeneDx this week, compared to 8 articles on an average week.

Search Interest

Only 1 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,808,056.00 in company stock.

Percentage Held by Insiders

25.17% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/09/2026
• Today: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:WGS
• CIK: 1818331
• Web: www.genedx.com
• Phone: 800-298-6470
• Fax: N/A
• Employees: 1,300
• Year Founded: 2000

Price Target and Rating

• Average Price Target for GeneDx: $90.14
• High Price Target: $150.00
• Low Price Target: $63.00
• Potential Upside/Downside: +60.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 49.00
• P/E Growth: N/A
• Net Income: -$21.02 million
• Net Margins: -23.41%
• Pretax Margin: -23.39%
• Return on Equity: 4.12%
• Return on Assets: 2.26%

Debt

• Debt-to-Equity Ratio: 0.40
• Current Ratio: 3.30
• Quick Ratio: 3.06

Sales & Book Value

• Annual Sales: $427.54 million
• Price / Sales: 3.93
• Cash Flow: $1.86 per share
• Price / Cash Flow: 30.25
• Book Value: $10.54 per share
• Price / Book: 5.35

Miscellaneous

• Outstanding Shares: 29,820,000
• Free Float: 22,317,000
• Market Cap: $1.68 billion
• Optionable: Optionable
• Beta: 2.00